Viewing Study NCT03678818


Ignite Creation Date: 2025-12-25 @ 4:31 AM
Ignite Modification Date: 2026-01-12 @ 8:12 AM
Study NCT ID: NCT03678818
Status: COMPLETED
Last Update Posted: 2019-05-07
First Post: 2018-09-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D007246', 'term': 'Infertility'}], 'ancestors': [{'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C037067', 'term': 'latrunculin A'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 300}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-09-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-05', 'completionDateStruct': {'date': '2019-04-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-05-05', 'studyFirstSubmitDate': '2018-09-17', 'studyFirstSubmitQcDate': '2018-09-17', 'lastUpdatePostDateStruct': {'date': '2019-05-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-09-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-04-20', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'oocyte survival rate', 'timeFrame': '6 days of culture'}], 'secondaryOutcomes': [{'measure': 'fertilization rate', 'timeFrame': '6 days of culture'}, {'measure': 'Blastocyst formation rate', 'timeFrame': '6 days of culture'}, {'measure': 'Blastocyst quality rate', 'timeFrame': '6 days of culture'}, {'measure': 'Clinical pregnancy rate', 'timeFrame': 'three months'}, {'measure': 'Implantation rate', 'timeFrame': '7 weeks'}, {'measure': 'Ongoing pregnancy rate', 'timeFrame': '12 weeks'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Infertility']}, 'descriptionModule': {'briefSummary': 'Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '42 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* ICSI participants\n\nExclusion Criteria:\n\n\\-'}, 'identificationModule': {'nctId': 'NCT03678818', 'briefTitle': 'Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Ibn Sina Hospital'}, 'officialTitle': 'Latrunculin A Supplementation to ICSI Handling Medium', 'orgStudyIdInfo': {'id': 'IbnSinaIVF-ICSI-LA'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Handling Medium Supplemented with Latrunculin A', 'interventionNames': ['Other: Medium Supplemented with Latrunculin A']}, {'type': 'NO_INTERVENTION', 'label': 'Handling Medium as it is.'}], 'interventions': [{'name': 'Medium Supplemented with Latrunculin A', 'type': 'OTHER', 'description': 'A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate', 'armGroupLabels': ['Handling Medium Supplemented with Latrunculin A']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Asyut', 'country': 'Egypt', 'facility': 'Banon Assiut', 'geoPoint': {'lat': 27.18096, 'lon': 31.18368}}, {'city': 'Sohag', 'country': 'Egypt', 'facility': 'IbnSina IVF Center', 'geoPoint': {'lat': 26.55695, 'lon': 31.69478}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Ibn Sina Hospital', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'IVF Lab Director', 'investigatorFullName': 'Muhammad Fawzy', 'investigatorAffiliation': 'Ibn Sina Hospital'}}}}